Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Failure (Hepatic Insufficiency) – Pipeline Review, H2 2016, provides an overview of the Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline landscape.
Liver failure is severe deterioration of liver function. Liver failure occurs when a large portion of the liver is damaged due to any type of liver disorder. Symptoms may include jaundice, tendency to bruise or bleed easily, ascites, impaired brain function (encephalopathy), poor weight gain and growth, fatigue, weakness, nausea and loss of appetite. Since these symptoms are associated with a host of other conditions, it may take some time before the correct diagnosis is made. As liver failure worsens, people may experience disorientation and drowsiness. At this stage, there is a risk of coma and death.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Liver Failure (Hepatic Insufficiency) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Liver Failure (Hepatic Insufficiency) (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Liver Failure (Hepatic Insufficiency) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, IND/CTA Filed, Preclinical and Discovery stages are 2, 4, 1, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.
Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Liver Failure (Hepatic Insufficiency) (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Liver Failure (Hepatic Insufficiency) (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Liver Failure (Hepatic Insufficiency) (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Liver Failure (Hepatic Insufficiency) (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Liver Failure (Hepatic Insufficiency) (Gastrointestinal)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Liver Failure (Hepatic Insufficiency) (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Liver Failure (Hepatic Insufficiency) (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned
Alfact Innovation
BioLineRx Ltd
Cell2B Advanced Therapeutics SA
Conatus Pharmaceuticals Inc
Immune Pharmaceuticals Inc
Mina Therapeutics Ltd
Mylan NV
Ocera Therapeutics Inc
PledPharma AB
Promethera Biosciences SA
Silence Therapeutics Plc
TGV-Laboratories
Unicyte AG
Ventria Bioscience
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Liver Failure (Hepatic Insufficiency) Overview 8
Therapeutics Development 9
Pipeline Products for Liver Failure (Hepatic Insufficiency) - Overview 9
Pipeline Products for Liver Failure (Hepatic Insufficiency) - Comparative Analysis 10
Liver Failure (Hepatic Insufficiency) - Therapeutics under Development by Companies 11
Liver Failure (Hepatic Insufficiency) - Therapeutics under Investigation by Universities/Institutes 12
Liver Failure (Hepatic Insufficiency) - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Unknown Stage Products 16
Liver Failure (Hepatic Insufficiency) - Products under Development by Companies 17
Liver Failure (Hepatic Insufficiency) - Products under Investigation by Universities/Institutes 18
Liver Failure (Hepatic Insufficiency) - Companies Involved in Therapeutics Development 19
Alfact Innovation 19
BioLineRx Ltd 20
Cell2B Advanced Therapeutics SA 21
Conatus Pharmaceuticals Inc 22
Immune Pharmaceuticals Inc 23
Mina Therapeutics Ltd 24
Mylan NV 25
Ocera Therapeutics Inc 26
PledPharma AB 27
Promethera Biosciences SA 28
Silence Therapeutics Plc 29
TGV-Laboratories 30
Unicyte AG 31
Ventria Bioscience 32
Liver Failure (Hepatic Insufficiency) - Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Target 34
Assessment by Mechanism of Action 36
Assessment by Route of Administration 38
Assessment by Molecule Type 40
Drug Profiles 42
ALF-5755 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Antisense RNAi Oligonucleotide for Liver Diseases - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
BL-1220 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
Cell Therapy for Liver Failure - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
emricasan - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
F-573 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Hep-114 - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
HepaStem - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
ImmuneSafe - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
MTL-CEBPA - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
Oligonucleotide for Liver Failure - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
ornithine phenylacetate - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
PP-100 - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
Recombinant Protein to Inhibit JNK for Liver Failure - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
RNAi Oligonucleotides to Inhibit MAP Kinase 4 for Liver Failure - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
silibinin - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
Small Molecules to Inhibit JNK for Type 2 Diabetes and Liver Failure - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
Stem Cell Therapy for Osteoarthritis, Diabetes Mellitus, Acute Liver Failure and Neurodegenerative Diseases - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
Stem Cell Therapy for Type 1 Diabetes, Urea Cycle Disorders and Acute Liver Failure - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
VEN-100 - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
Liver Failure (Hepatic Insufficiency) - Dormant Projects 76
Liver Failure (Hepatic Insufficiency) - Discontinued Products 77
Liver Failure (Hepatic Insufficiency) - Product Development Milestones 78
Featured News & Press Releases 78
Oct 24, 2016: Ocera Therapeutics Announces Late-Breaker Abstract Accepted for Presentation at the AASLD Liver Meeting 2016 78
Sep 21, 2016: Ocera Announces Enrollment Completion From Phase 2a NIH-Sponsored Study of OCR-002 in the Treatment of Patients with Acute Liver Failure 78
Nov 19, 2015: Marina Biotech Reports pre-clinical data on its MTL-CEBPA at the 2015 American Association for the Study of Liver Diseases 78
Nov 16, 2015: Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting 79
Oct 05, 2015: Ocera Therapeutics Highlights OCR-002 Data to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases 80
Jan 08, 2015: Conatus Announces Top-Line Results From ACLF and Organ Impairment Clinical Trials of Emricasan 81
Jan 05, 2015: Conatus to Report Top-line Results From ACLF and Organ Impairment Clinical Trials of Emricasan 83
Nov 02, 2013: Conatus Pharmaceuticals Presents Data Demonstrating Emricasan's Safety Profile at the AASLD Liver Meeting 83
Apr 11, 2013: Gene inhibition helps to improve liver regeneration 84
Apr 02, 2013: ALF-5755 phase II completion 85
Nov 08, 2012: Ocera Therapeutics Enrolls First Patient In Phase IIa Study Of OCR-002 In Treatment Of Patients With Acute Liver Injury 85
Aug 03, 2012: MDC Researchers Develop New Approach to Treat Acute Liver Failure 86
May 06, 2011: ALF-5755 phase II extends to Germany 87
May 05, 2011: Alfact Innovation Receives Orphan Drug Designation For ALF-5755 From FDA 87
Appendix 88
Methodology 88
Coverage 88
Secondary Research 88
Primary Research 88
Expert Panel Validation 88
Contact Us 88
Disclaimer 89
List of Tables
Number of Products under Development for Liver Failure (Hepatic Insufficiency), H2 2016 9
Number of Products under Development for Liver Failure (Hepatic Insufficiency) - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Number of Products under Investigation by Universities/Institutes, H2 2016 12
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Clinical Stage Development, H2 2016 14
Comparative Analysis by Early Stage Development, H2 2016 15
Comparative Analysis by Unknown Stage Development, H2 2016 16
Products under Development by Companies, H2 2016 17
Products under Investigation by Universities/Institutes, H2 2016 18
Liver Failure (Hepatic Insufficiency) - Pipeline by Alfact Innovation, H2 2016 19
Liver Failure (Hepatic Insufficiency) - Pipeline by BioLineRx Ltd, H2 2016 20
Liver Failure (Hepatic Insufficiency) - Pipeline by Cell2B Advanced Therapeutics SA, H2 2016 21
Liver Failure (Hepatic Insufficiency) - Pipeline by Conatus Pharmaceuticals Inc, H2 2016 22
Liver Failure (Hepatic Insufficiency) - Pipeline by Immune Pharmaceuticals Inc, H2 2016 23
Liver Failure (Hepatic Insufficiency) - Pipeline by Mina Therapeutics Ltd, H2 2016 24
Liver Failure (Hepatic Insufficiency) - Pipeline by Mylan NV, H2 2016 25
Liver Failure (Hepatic Insufficiency) - Pipeline by Ocera Therapeutics Inc, H2 2016 26
Liver Failure (Hepatic Insufficiency) - Pipeline by PledPharma AB, H2 2016 27
Liver Failure (Hepatic Insufficiency) - Pipeline by Promethera Biosciences SA, H2 2016 28
Liver Failure (Hepatic Insufficiency) - Pipeline by Silence Therapeutics Plc, H2 2016 29
Liver Failure (Hepatic Insufficiency) - Pipeline by TGV-Laboratories, H2 2016 30
Liver Failure (Hepatic Insufficiency) - Pipeline by Unicyte AG, H2 2016 31
Liver Failure (Hepatic Insufficiency) - Pipeline by Ventria Bioscience, H2 2016 32
Assessment by Monotherapy Products, H2 2016 33
Number of Products by Stage and Target, H2 2016 35
Number of Products by Stage and Mechanism of Action, H2 2016 37
Number of Products by Stage and Route of Administration, H2 2016 39
Number of Products by Stage and Molecule Type, H2 2016 41
Liver Failure (Hepatic Insufficiency) - Dormant Projects, H2 2016 76
Liver Failure (Hepatic Insufficiency) - Discontinued Products, H2 2016 77
List of Figures
Number of Products under Development for Liver Failure (Hepatic Insufficiency), H2 2016 9
Number of Products under Development for Liver Failure (Hepatic Insufficiency) - Comparative Analysis, H2 2016 10
Number of Products under Development by Companies, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 15
Assessment by Monotherapy Products, H2 2016 33
Number of Products by Top 10 Targets, H2 2016 34
Number of Products by Stage and Top 10 Targets, H2 2016 34
Number of Products by Top 10 Mechanism of Actions, H2 2016 36
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 36
Number of Products by Routes of Administration, H2 2016 38
Number of Products by Stage and Routes of Administration, H2 2016 38
Number of Products by Molecule Types, H2 2016 40
Number of Products by Stage and Molecule Types, H2 2016 40
